Advances in the identification and management of progressive pulmonary fibrosis: perspective from Chinese experts
H Huang, Q Wang, Z Xu - Therapeutic Advances in …, 2024 - journals.sagepub.com
Fibrosing interstitial lung diseases (FILDs) other than idiopathic pulmonary fibrosis (IPF) can
develop into progressive pulmonary fibrosis (PPF) despite initial management. A substantial …
develop into progressive pulmonary fibrosis (PPF) despite initial management. A substantial …
Diagnosis and management of hypersensitivity pneumonitis in adults: A position statement from the Thoracic Society of Australia and New Zealand
H Barnes, TJ Corte, G Keir, YH Khor, S Limaye… - …, 2024 - Wiley Online Library
Hypersensitivity pneumonitis (HP) is an immune‐mediated interstitial lung disease (ILD)
relating to specific occupational, environmental or medication exposures. Disease …
relating to specific occupational, environmental or medication exposures. Disease …
Generalizability of pharmaceutical randomized controlled trial eligibility criteria for progressive pulmonary fibrosis
YH Khor, KA Johannson, V Marcoux… - European …, 2024 - publications.ersnet.org
Background Progressive pulmonary fibrosis (PFF) is of substantial interest for novel
pharmacotherapy discovery, but little is known about clinical trial eligibility criteria. We …
pharmacotherapy discovery, but little is known about clinical trial eligibility criteria. We …
Criteria for progressive fibrotic hypersensitivity pneumonitis in a Portuguese patient cohort
E Seixas, M Ferreira, P Serra, R Aguiar… - African Journal of …, 2022 - journals.co.za
Background Hypersensitivity pneumonitis (HP) is a syndrome caused by sensitisation to
inhaled antigens that leads to an abnormal immune response in the airways and lung …
inhaled antigens that leads to an abnormal immune response in the airways and lung …
[引用][C] Étude du rôle des lymphocytes B dans le développement de la pneumopathie d'hypersensibilité
O Courtemanche - 2022